Twenty-sixth listing of 2021 on Euronext Growth Milan
Medica S.p.A. brings the total number of companies listed on Euronext Growth Milan to 157
Total placement volume of the offering equal to €22.9 million
Milan – 3 November 2021 – Borsa Italiana, part of the Euronext Group, today congratulates Medica S.p.A. on its listing on Euronext Growth Milan.
Medica S.p.A. operates in the biomedical sector. The company’s core business is the development of innovative products for blood purification.
Medica S.p.A. represents the twenty-sixth listing since the beginning of the year on Borsa Italiana’s market dedicated to small and medium sized companies and it brings the total number of firms currently listed on Euronext Growth Milan to 157.
In the placement phase, Medica S.p.A. raised €20.2 million, excluding the potential exercise of an over-allotment option. In the case of full exercise of the over-allotment option, the total amount raised will be €22.9 million. The free float at the time of admission was 17.7% and the market capitalisation at IPO was €114.0 million.
Luciano Fecondini, Chairman and CEO of Medica S.p.A., said:
"We are certainly proud of the results of the IPO process. Thanks to the listing, we will have the resources to carry on with innovative projects of significant size, and to accelerate our growth through focused and synergistic acquisitions. We also welcome the presence of international investors among new shareholders, in line with our international footprint. Listing on Euronext Growth Milan is a first step towards the achievement of an ambitious, long-term vision, being aware of our growth potential both in the medical and water purification fields."
Luciano Fecondini, Chairman and CEO of Medica S.p.A., rang the bell during the market open ceremony this morning to celebrate the Initial Public Offering of the company.
About Medica Group Medica Group has been in operation since 1985 in the Mirandola Biomedical District of (Italy). Development of innovative products for blood puriﬁcation has always been company’s core business. Thanks to the activity of two extremely dynamic R&D groups (medical equipment, membranes and disposables), the Group competes successfully in several markets, namely:
Medical (dialysis, CRRT, ECCO2, Apheresis, DFPP, CHF, HIPEC, pre-transplant organ perfusion, bioregenerative medicine, gastroenterology, urodynamics, oxygen humidification)
Microbiological purification of water
Industrial automation for the biomedical sector
R&D focus has been integrated over the years with highly automated production systems in five different facilities, four in Italy and one in Tunisia, and two commercial entities (in the US and in China). The key success factors of the Group are:
Extrusion of hollow fibre membranes for hemofiltration, plasmapheresis, cascade filtration, oxygen humidification, ultrafiltration and microfiltration of water
Vertical integration, proven by the ability to manage not only the design and development of medical disposables and equipment, but also the development of the automation technologies required for their production.
International recognition with significant share of export (69% of revenues in 2020), with sales in over 60 countries.